Long-Term Clinical Outcomes of Patients with Differentiated Thyroid Cancer Treated with Lenvatinib: Results from Real-World Practice in Japan
Authors' conclusion
In patients with RAI-refractory DTC treated with lenvatinib, careful treatment optimization and management of adverse events contribute to a favorable, durable prognosis.
Study context
- Population
- Patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) treated with lenvatinib 2011–2022, National Cancer Center Hospital East, Japan; 64.8% papillary, 24.2% follicular carcinoma
- Participants
- 91 patients
- Outcome
- Median PFS and OS with lenvatinib (single group)
- Follow-up
- Median observation 2.9 years (range, 0.1-12.4; IQR, 1.7-4.6)
Methodological detailssingle-centre, Some patients were enrolled in a prospective clinical trial
- Single-centre
- Some patients were enrolled in a prospective clinical trial
Main finding
As reported in the abstract
median observation 2.9 years (range, 0.1-12.4; IQR, 1.7-4.6)
Median progression-free survival
2.4 years
95% CI 1.9–3.3
Median overall survival
5.1 years
95% CI 3.3–6.7
Observational data: associations, not effects.
Further findings
Management received
- Planned drug holidays
- n = 72, 79.1%
- Dose escalation at systemic progression
- n = 21, 23.1%
- Local therapy for oligoprogressive disease
- n = 11, 12.1%
Safety
Adverse events · data cutoff
- Discontinued lenvatinib due to adverse events
- 19.8%
- Grade 5 adverse events
- 0
Original publication
Long-Term Clinical Outcomes of Patients with Differentiated Thyroid Cancer Treated with Lenvatinib: Results from Real-World Practice in Japan. Thyroid. Published 9 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →